PDCD1 and non-small cell lung carcinoma: A retrospective study included 42 patients with NSCLC treated with PD-1 antibody monotherapy or combined PD-1 and CTLA-4 blockade and examined the evolving neoantigen landscape during the emergence of acquired resistance [73].